The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds of the present invention can be advantageously used to treat patients...http://www.google.es/patents/US7384973?utm_source=gb-gplus-sharePatente US7384973 - Materials and methods for treating hypercholesterolemia
Materials and methods for treating hypercholesterolemia
